<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97510">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982357</url>
  </required_header>
  <id_info>
    <org_study_id>LAMMP-30303</org_study_id>
    <nct_id>NCT01982357</nct_id>
  </id_info>
  <brief_title>Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies</brief_title>
  <official_title>Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montana Compton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alterations to microvascular blood flow in premature infants, are known to contribute to
      several major disease entities.

      The optically-measured tissue blood flow, to determine tissue perfusion that can be use to
      detect blood loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researchers want to use optical technologies to non-invasively detect blood flow that
      can tell the onset of blood loss. The research can measure blood flow in stable premature
      infants in the Neonatal Intensive Care Unit over the duration of several weeks.

      The technologies are Laser Speckle Imaging and Diffuse Optical Spectroscopy.

      Laser Speckle Imaging non-contact imaging technology, is sensitive to blood flow in
      superficial tissues. Diffuse Optical Spectroscopy, a probe-based contact technology like
      pulse oximetry, measures hemoglobin concentrations and states deeper below the skin surface.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>changes in tissue blood flow in premature infants.</measure>
    <time_frame>appoximately within 5 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Infant, Premature, Diseases</condition>
  <arm_group>
    <arm_group_label>premature infant</arm_group_label>
    <description>Laser Speckle Imaging and Diffuse Optical Spectroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Speckle Imaging and Diffuse Optical Spectroscopy</intervention_name>
    <description>Laser Speckle Imaging and Diffuse Optical Spectroscopy</description>
    <arm_group_label>premature infant</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        premature infants
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature infants born or transfered to neonatal intensive care unit with a
             gestational age of 28-35 weeks

        Exclusion Criteria:

          -  NONE premature infants born or transfered to neonatal intensive care unit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omid Fathi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute, UCI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCIMC</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Montana Compton</investigator_full_name>
    <investigator_title>Research Nurse</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infant, Premature, Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
